BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects

E-ISSN： 1873-5576|14|2|128-143

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.14, Iss.2, 2014-02, pp. : 128-143

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Novel Treatment Approach for Extensive, Eruptive, Cutaneous Squamous Cell Carcinomas in a Patient Receiving BRAF Inhibitor Therapy for Metastatic Melanoma

By Fathi Ramin Kamalpour Loebat Gammon Bryan Tung Rebecca

Dermatologic Surgery, Vol. 39, Iss. 2, 2013-02 ,pp. : 341-344

Elsevier

Access to resources Recommend Favorite

Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas

By Lo Roger S

Pharmacogenomics, Vol. 13, Iss. 2, 2012-01 ,pp. : 125-128

Future Medicine

Access to resources Recommend Favorite

The future of targeted therapy approaches in melanoma

By Cantini Liliana P Meier Friedegund Sondak Vernon K Smalley Keiran SM

Expert Opinion on Drug Discovery, Vol. 4, Iss. 4, 2009-04 ,pp. : 445-456

Informa Healthcare

Access to resources Recommend Favorite

Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies

By Gibney Geoffrey T

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 7, 2013-07 ,pp. : 893-899

Informa Healthcare

Access to resources Recommend Favorite

Prospects for future therapy of HCV infection

By Sakamoto Naoya Wu George Y

Future Virology, Vol. 4, Iss. 5, 2009-09 ,pp. : 453-462

Future Medicine

Access to resources Recommend Favorite